Thursday, 29 October 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Business Update

Beta Drugs Business Update

Beta Drugs secured Azerbaijani regulatory approvals for its oncology portfolio across multiple dosage forms. The company targets Azerbaijan commercialisation during the current financial year.

Source

NSE filing, NSE: BETA. Summary written from the filing by ALFA Finder's alert engine.

Read the filing ↗

Beta Drugs Ltd: key numbers

Share price
₹1,976.80
Market cap
₹2,191 Cr
Revenue (annual)
₹384.8 Cr
Net profit (annual)
₹41.48 Cr
P/E (TTM)
42.2×Sector 46.1×
Promoter holding
58.91%-0.19% QoQ
FII holding
1.37%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Beta Drugs Ltd

All →

Other business update announcements

All →